



# HHS Public Access

Author manuscript

*Eur Respir J.* Author manuscript; available in PMC 2017 November 01.

Published in final edited form as:

*Eur Respir J.* 2016 November ; 48(5): 1442–1452. doi:10.1183/13993003.00129-2016.

## High Attenuation Areas on Chest CT in Community-Dwelling Adults: The MESA Study

Anna J. Podolanczuk, MD<sup>1,\*</sup>, Elizabeth C. Oelsner, MD<sup>1,\*</sup>, R. Graham Barr, MD<sup>1,2</sup>, Eric A. Hoffman, PhD<sup>3</sup>, Hilary F. Armstrong, MPhil<sup>2</sup>, John H.M. Austin, MD<sup>4</sup>, Robert C. Basner, MD<sup>1</sup>, Matthew N. Bartels, MD<sup>5</sup>, Jason D. Christie, MD<sup>6</sup>, Paul L. Enright, MD<sup>7</sup>, Bernadette R. Gochuico, MD<sup>8</sup>, Karen Hinckley Stukovsky, MS<sup>9</sup>, Joel D. Kaufman, MD<sup>10</sup>, P. Hrudaya Nath, MD<sup>11</sup>, John D. Newell Jr, MD<sup>3</sup>, Scott M. Palmer, MD<sup>12</sup>, Dan Rabinowitz, PhD<sup>13</sup>, Ganesh Raghu, MD<sup>10</sup>, Jessica L. Sell, MPH<sup>1</sup>, Jered Sieren<sup>14</sup>, Sushil K. Sonavane, MD<sup>11</sup>, Russell P. Tracy, PhD<sup>15</sup>, Jubal R. Watts, MD<sup>11</sup>, Kayleen Williams, MPH<sup>10</sup>, Steven M. Kawut, MD<sup>16</sup>, and David J. Lederer, MD<sup>1,2</sup>

<sup>1</sup>Department of Medicine, Columbia University Medical Center, 161 Fort Washington, New York, NY, USA

<sup>2</sup>Department of Epidemiology, Columbia University Medical Center, 161 Fort Washington, New York, NY, USA

<sup>3</sup>Departments of Radiology, Medicine, and Biomedical Engineering, University of Iowa Carver College of Medicine, 451 Newton Road, Iowa City, IA, USA

<sup>4</sup>Department of Radiology, Columbia University Medical Center, 161 Fort Washington, New York, NY, USA

<sup>5</sup>Department of Rehabilitation Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, 111 East 210th Street, Bronx, NY, USA

<sup>6</sup>Department of Medicine and the Center for Translational Lung Biology, University of Pennsylvania, 423 Guardian Drive, 717 Blockley Hall, Philadelphia, PA, USA

<sup>7</sup>Department of Epidemiology, University of Arizona, 1295 N. Martin Ave, PO Box 245163, Tucson, AZ, USA

<sup>8</sup>National Human Genome Research Institute, 10 Center Dr, Bethesda, MD, USA

---

Corresponding Author: David J Lederer, MD, MS, Associate Professor of Medicine and Epidemiology, Columbia University Medical Center, 161 Fort Washington Ave, Room 3-321A, New York, NY 10032, Phone: 212-305-8203, Fax: 212-305-8426, davidlederer@columbia.edu.

\*These authors contributed equally to this work

### Authors' Contributions:

AP, ECO, DJL, RGB, and SMK conceived and designed the study.

AP, ECO, RGB, HFA, RCB, MNB, JDC, KHS, JDK, SMP, RPT, KW, and DJL acquired the data.

AP, ECO, RGB, EAH, JHMA, RCB, MNB, KHS, PHN, JDN, DR, JLS, JS, SKS, RPT, JRW, KW, and DJL analyzed the data.

All authors contributed to interpretation of data

AP drafted the initial manuscript

All authors revised the manuscript for important intellectual content and approved the final version of the manuscript

All authors agree to be accountable for all aspects of the work

**Study Summary:** Areas of increased lung attenuation on CT may identify subclinical lung injury and inflammation in community-dwelling adults.

<sup>9</sup>Department of Biostatistics, University of Washington, 4225 Roosevelt Way NE, Seattle, WA, USA

<sup>10</sup>Department of Medicine, University of Washington, 4225 Roosevelt Way NE, Seattle, WA, USA

<sup>11</sup>Department of Radiology, University of Alabama, Jefferson Tower, Room N370, 625 19th Street, South Birmingham, AL, USA

<sup>12</sup>Duke Clinical Research Institute, Duke University, 2085 Msrb2 2 Genome Ct, Durham, NC, USA

<sup>13</sup>Department of Statistics, Columbia University, 161 Fort Washington, New York, NY, USA

<sup>14</sup>VIDA Diagnostics, Inc., 2500 Crosspark Rd, W250 BioVentures Center, Coralville, IA, USA

<sup>15</sup>Department of Pathology, University of Vermont, 360 South Park Drive, Colchester, VT, USA

<sup>16</sup>Department of Medicine and the Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, 423 Guardian Drive, 718 Blockley Hall, Philadelphia, PA, USA

## Abstract

Evidence suggests that lung injury, inflammation and extracellular matrix remodeling precede lung fibrosis in interstitial lung disease (ILD). We examined whether a quantitative measure of increased lung attenuation on computed tomography (CT) detects lung injury, inflammation and extracellular matrix remodeling in community-dwelling adults sampled without regard to respiratory symptoms or smoking.

We measured high attenuation areas (HAA; percentage of lung voxels between -600 and -250 Hounsfield Units) on cardiac CT scans of adults enrolled in the Multi-Ethnic Study of Atherosclerosis.

HAA was associated with higher serum matrix metalloproteinase-7 (mean adjusted difference 6.3% per HAA doubling, 95% CI 1.3 to 11.5), higher interleukin-6 (mean adjusted difference 8.8%, 95% CI 4.8 to 13.0), lower forced vital capacity (mean adjusted difference -82 mL, 95% CI -119 to -44), lower 6-minute walk distance (mean adjusted difference -40 m, 95% CI -1 to -80), higher odds of interstitial lung abnormalities at 9.5 years (adjusted OR 1.95, 95% CI 1.43 to 2.65), and higher all cause-mortality rate over 12.2 years (HR 1.58, 95% CI 1.39 to 1.79).

High attenuation areas are associated with biomarkers of inflammation and extracellular matrix remodeling, reduced lung function, interstitial lung abnormalities, and a higher risk of death among community-dwelling adults.

---

## Introduction

Recurrent alveolar epithelial cell injury, lung inflammation, and dysregulated extracellular matrix remodeling are thought to be key precursor events that lead to lung fibrosis in interstitial lung disease (ILD) [1, 2]. Adults with ILD typically develop symptoms years after the initial insult, making the antecedent causes of lung fibrosis difficult to identify. Studies of humans with subclinical disease may provide novel insights into the early

mechanisms of lung injury, yet until recently few studies have looked at interstitial lung changes prior to the development of symptoms [3-5].

Recent recognition of interstitial lung abnormalities (ILA) on chest CT scans of participants in large population cohorts has advanced our understanding of early interstitial lung disease [6-9]. Interstitial lung abnormalities have been shown to be associated with cigarette smoking [6], reduced lung volumes [6], reduced exercise capacity [7], MUC5b polymorphism [8], and all-cause mortality [9] in population-based cohorts. However, ILA assessment is labor intensive, requiring visual scoring by trained readers, and may at times exclude equivocal and indeterminate findings that may have clinical significance. An automated approach might provide superior reproducibility and greater sensitivity for early abnormalities not detectable by the human eye, including changes that might precede visual identification of ILA.

We have previously proposed that a quantitative measure of lung attenuation on computed tomography (CT), termed high attenuation areas (HAA), might be a suitable measure of early pathological processes in the lung that precede ILD [10]. We reported that a greater volume of HAA in the lung is associated with cigarette smoking [10]. Others reported that adults with HAA involving more than 10% of the lung have reduced total lung capacity and an increased odds of ILA in cross-sectional analyses [11]. However, further construct validity of HAA as a quantitative measure of early lung injury, inflammation, or fibrosis is lacking and the significance of smaller amounts of HAA is not known.

In the current study, we therefore sought to determine whether HAA is associated with features of subclinical lung injury, inflammation, and fibrosis, including higher levels of serum biomarkers of inflammation (interleukin-6 (IL-6) and c-reactive protein (CRP)) and lung remodeling (surfactant protein-A (SP-A) and matrix metalloproteinase-7 (MMP-7)), reduced forced vital capacity (FVC), reduced exercise capacity, increased odds of visually-identified ILA, and all-cause mortality in community dwelling adults. We chose IL-6 and CRP because of their well-characterized roles in systemic inflammation [12, 13], and MMP-7 and SP-A based on prior studies showing associations of these biomarkers with lung injury and extracellular matrix remodeling in ILD [14-20].

## Methods

Full methods are available in the Supplementary Appendix.

### Study Participants

The Multi-Ethnic Study of Atherosclerosis (MESA) is a multi-center, National Heart Lung and Blood Institute (NHLBI)-sponsored U.S.-based prospective cohort study designed to investigate subclinical cardiovascular disease. Enrollment criteria have previously been described [21]. Briefly, the study enrolled 6,814 adults age 45 and 84 years free of clinical cardiovascular disease from six communities in the United States between 2000 and 2002. There were no selection criteria based on lung disease, respiratory symptoms, or smoking history. MESA participants attended follow-up visits, with the most recent visit between 2010 and 2012 (Figure S1) [21]. Vital status was determined by contacting each participant

or family member every 9 to 12 months. This was supplemented through review of the National Death Index (NDI) to ensure complete follow-up of mortality through the most recent NDI update (March 13, 2015).

MESA served as the sampling frame for our study. We sampled MESA participants for three substudies: biomarkers, lung function & ILA measurement, and exercise testing. Our sampling strategies for each substudy are described in detail in the Supplementary Appendix and in Figure S2. The sample size for each substudy is reported alongside the results of each substudy.

We also included a comparator group of 48 adults with clinically diagnosed ILD (75% with IPF) seen at one of 3 centers (Columbia, Penn, or Duke) who were enrolled in the NHLBI-funded Lung Transplant Body Composition (LTBC) study.

MESA, LTBC, and all ancillary studies were approved by Institutional Review Boards at all collaborating centers and all participants provided informed consent.

### High Attenuation Areas on CT Scans

HAA was measured on non-contrast cardiac CT scans performed at the MESA baseline visit in 2000-02 on multi-detector CT scanners (three sites) or electron beam tomography scanners (three sites) using a previously described standardized protocol [22]. Each participant underwent two sequential scans on separate breath-holds in succession at full inspiration, with transverse fields of view capturing the whole lung field from the carina to the lung bases. The scan with higher air volume was used for analyses, except in cases of discordant scan quality control score, in which case the higher quality scan was used [23]. Details of the CT protocols are shown in Table S1 in the Supplementary Appendix. A prior validation study using MESA full lung scans showed that these cardiac CT scans image approximately 65% of total lung volume, excluding most of the upper lobes but capturing most of the lower lobes [23]. HAA was defined as the percent of imaged lung volume having CT attenuation between -600 and -250 Hounsfield Units (HU), as previously described [10]. Percent emphysema was defined as the percentage of voxels below -950 HU [24]. LTBC participants underwent full lung inspiratory CT imaging according to clinical protocols at each site. Quantitative image attenuation was measured using a modified version of the Pulmonary Analysis Software by trained readers at Dr. Hoffman's University of Iowa Imaging Lab.

### Biomarker Measurements

MMP-7, SP-A, and interleukin-6 (IL-6) were measured in banked baseline serum samples using ELISA assays from R&D systems (MMP-7 and IL-6) and Biovendor (SP-A). Baseline serum C-reactive protein (CRP) was measured using a BNII nephelometer. All measurements were performed by the MESA Core Laboratory at the University of Vermont's Laboratory for Clinical Biochemistry Research. Additional assay characteristics are provided in the Supplementary Appendix.

## Spirometry and Exercise Testing

Spirometry was conducted according to the American Thoracic Society (ATS)/European Respiratory Society guidelines [25], as previously described [26]. Six-minute walk test (6-MWT) was conducted in accordance with ATS guidelines without supplemental oxygen [27]. CPET was performed on a Vmax Encore 29 Metabolic Exercise System, Viasprint 150P (Viasys Respiratory Care, Yorba Linda, CA) with an electrically braked cycle ergometer.

## Interstitial Lung Abnormalities

Full lung MESA CT scans were acquired in years 2010-12 at suspended full inspiration on 64-slice scanners (GE and Siemens) using the MESA Lung/SPIROMICS protocol (See supplementary appendix) [28]. Images were reconstructed using 0.625 mm slice thickness, as previously described [29]. ILA was defined as the presence of ground-glass, reticular abnormality, diffuse centrilobular nodularity, honeycombing, traction bronchiectasis, non-emphysematous cysts or architectural distortion in at least 5% of nondependent portions of the lung, using methodology previously described [6, 8, 30].

## Analysis Approach

We treated HAA as a continuous independent log base-2 (binary) transformed variable. For most analyses, we used generalized linear models adjusted for age, gender, race/ethnicity, educational attainment, height, BMI, waist circumference, smoking status, cigarette pack-years, glomerular filtration rate (GFR), study site, mA dose, total volume of imaged lung and percent emphysema. Since FVC and imaged lung volume were collinear (Pearson correlation coefficient of 0.7), we excluded imaged lung volume from analyses examining the association between HAA and FVC.

We used logistic regression to estimate adjusted odds ratios for ILA. Given the small sample size of the exercise substudy, we chose a case-control design. We defined HAA cases as having the highest decile of HAA (>7.5% of total imaged lung) and we present age- and gender-adjusted least-square mean values. Details of sampling for analyses of MMP-7 and SP-A are provided in the Supplementary Appendix.

We examined associations between HAA and survival time using Cox proportional hazards models and additive Cox models, as previously described [31]. Survival time was calculated as the age at death or last follow-up or the most recent National Death Index update, whichever occurred later. Primary analyses were adjusted for the above covariates. Secondary analyses were further adjusted for alcohol use, exercise, history of cancer, coronary artery calcification, and the cardiovascular risk factors listed in the footnote to Table 3.

We examined models stratified by smoking status, age, gender, race/ethnicity and BMI. We performed sensitivity analyses excluding participants in the highest decile of HAA (>7.5% of total imaged lung) and adjusting for measures of cardiac systolic and diastolic function. We compared mean HAA values among community-dwelling adults to HAA values in 48 adults clinically diagnosed with ILD using the Wilcoxon rank sum test.

All statistical tests were performed in SAS version 9.3 (SAS Institute) and R version 3.2.0 (R Foundation for Statistical Computing).

## Results

One participant was excluded from analyses due to lack of valid baseline HAA assessment (Figure S2). The baseline characteristics of the 6,813 remaining MESA participants are shown in Tables S2 and S3 in the Supplementary Appendix. MESA participants had a mean age of 62 years; 53% were men; 38% were white, 28% were African-American, 22% were Hispanic and 12% were Asian. 55% of MESA participants were former or current smokers who smoked a median of 15 cigarette pack-years. The 48 LTBC participants had a mean age of 63 years (range 34-75 years), 31% were women, and 75% had IPF.

MESA participants had a mean (SD) HAA value of 5.1% (3.1%) with a range of 1.2% to 48.9%. LTBC participants with clinically diagnosed ILD had a mean (SD) HAA value of 25.4% (8.8%) with a range of 9.3% to 50.8% (Wilcoxon rank sum p-value <0.001 vs. MESA participants; Figure 1A). MESA participants with greater HAA were more likely to be female, Hispanic or Chinese, never-smokers, and had higher BMIs than those with lower HAA values (Table S2). Those in the higher HAA quartiles also tended to have a lower volume of imaged lung and lower percent emphysema.

### Visual Appearance of HAA on CT

MESA participants with elevated HAA (defined arbitrarily as greater than 7.5%) had a range of abnormalities on visual inspection of CT images [10]. Common abnormalities included ground-glass and reticular changes. Figure 1 shows selected CT images from four MESA participants with HAA >90<sup>th</sup> percentile at baseline who also had ILA at 10-year follow-up.

### Serum biomarkers

There were 908 MESA participants who had MMP-7 and SP-A measured (see Supplementary Appendix). IL-6 was measured in 6,621 participants, and CRP was measured in 6,671 participants. Greater HAA was associated with higher serum MMP-7 and IL-6 levels (Table 1 and S4). For each doubling of HAA, there was a 6.26% increment in MMP-7 (95% CI 1.29 to 11.47; p=0.01; Figure 3a) and an 8.78% in IL-6 (95% CI 4.77 to 12.95; p<0.001; Figure 3b). The association between HAA and MMP-7 was modified by smoking status (p for interaction <0.001). Each doubling in HAA was associated with a 15.45% increment in MMP-7 (95% CI 7.91 to 23.53; p<0.001) among ever-smokers and a 1.39% increase in MMP-7 (95% CI -5.36 to 8.62; p=0.69; Table 1) among never-smokers. The association between HAA and IL-6 tended to be stronger among ever-smokers albeit with only modest evidence of effect modification (p for interaction 0.11; Table 1). We found no significant association between HAA and CRP or SP-A levels (Table 1).

### Spirometry

There were 3,834 MESA participants who completed spirometry and had had valid measures of FEV<sub>1</sub> and FVC (see Supplementary Appendix). In a fully adjusted model, each doubling of HAA was associated with an 82 mL decrement in FVC (95% CI 119 to 44;



$p < 0.001$ ) and a 2.8% absolute decrement in percent predicted FVC (95% CI 3.9 to 1.7;  $p < 0.001$ ; Table S5) in MESA. This association was modified by smoking status ( $p$  for interaction 0.002). In a fully adjusted model, each doubling of HAA was associated with a 157 mL decrement in FVC (95% CI 216 to 97;  $p < 0.001$ ; Table S5) among ever-smokers and a 15 mL decrement (95% CI 60 to -31;  $p = 0.53$ ; Table S5) among never-smokers. We found similar associations for FEV<sub>1</sub> and percent predicted FEV<sub>1</sub> but not for the ratio of FEV<sub>1</sub> to FVC (Table S6).

### Exercise capacity

There were 89 MESA participants who completed exercise testing; 30 of these were cases (had HAA above the 90<sup>th</sup> percentile (7.5%)) and 59 were controls (HAA below the 90<sup>th</sup> percentile). Cases with high HAA had diminished exercise capacity by both 6-MWT and CPET compared to controls (Figure 2). After adjustment for age and gender, the least squares mean difference was 40 m (95% CI 1 to 80;  $p = 0.045$ ; Table S7). HAA cases also had lower adjusted peak  $\dot{V}O_2$  (1.28 vs. 1.47 L/min;  $p = 0.01$ ), percent predicted peak  $\dot{V}O_2$  (72% vs. 83%;  $p = 0.01$ ) and peak Watts (76 vs. 88 W;  $p = 0.02$ ; Figure 2 and Table S7). Breathing reserve was lower among cases than controls (53 vs. 61%;  $p = 0.04$ ), suggesting a ventilatory limitation to exercise. There were no significant differences between cases and controls in heart rate, O<sub>2</sub> pulse,  $\dot{V}E/\dot{V}CO_2$ , and end-tidal CO<sub>2</sub> at peak exercise.

### Interstitial Lung Abnormalities

There were 2,907 MESA participants who had a valid qualitative assessment of ILA. The median time between HAA measurement and ILA assessment was 9.5 years (range 8.0 to 11.4 years). Of these 2,907 scans, 477 (16.5%) were read as equivocal for ILA and were excluded from further ILA analyses. Of the remaining 2,430 participants, 306 (10.5% of the overall sample) had ILA: 285 (9.8%) had scans read as suspicious for ILD and 21 (0.7%) had scans showing bilateral fibrosis in multiple lobes associated with honeycombing and traction bronchiectasis in a subpleural distribution (definite ILD). 162 participants (53%) with ILA had changes that were primarily in the subpleural distribution. The distribution of the types of abnormalities is shown in Table S8 in the Supplementary Appendix.

The number of participants with ILA increased across quartiles of HAA ( $p$  for trend  $< 0.001$ ; Table 2). In fully adjusted models, those with baseline HAA values greater than 5.3% (4<sup>th</sup> quartile) had a 3-fold higher odds of ILA compared to those in the lowest quartile (OR 3.07, 95% CI 1.77 to 5.33;  $p < 0.001$ ; Table 2 and Figure 3c), and each doubling of HAA was associated with a 95% increased odds of ILA (OR 1.95, 95% CI 1.43 to 2.65,  $p$  value  $< 0.001$ ). These findings were similar among ever-smokers and never-smokers (Table 2). Analyses in which participants with equivocal ILA findings were included as “no ILA” yielded similar results (Table S9).

### Mortality

Five participants were excluded from follow-up by the MESA Events Committee because of discovery of pre-baseline cardiovascular events, and no mortality data is available for these participants. There were 1,093 deaths among the remaining 6,808 MESA participants over a median follow-up of 12.2 years (range 0 to 14.2). Greater HAA was associated with higher

all-cause mortality (Figure 3d). In fully adjusted models, MESA participants in the highest quartile of HAA had approximately a doubling of the rate of death compared to those in the lowest HAA quartile (HR 1.94, 95% CI 1.53 to 2.46; p for trend <0.001; Table 3) and each doubling of HAA was associated with a 55% increase in the rate of death from any cause (HR 1.55, 95% CI 1.37 to 1.77, p value <0.001) without evidence of modification by smoking status.

### Additional Analyses

Stratified and sensitivity analyses, including adjustment for left ventricular function and restriction to those participants with HAA less than 7.5%, are shown in Tables S10-S12. These analyses did not substantially change our findings.

### Discussion

We have shown that areas of high CT attenuation in the lungs of community-dwelling middle aged and older adults were associated with elevated serum levels of MMP-7 and IL-6, reduced forced vital capacity, reduced exercise capacity, greater odds of ILA at ten-year follow-up, and a higher mortality rate. Some of these associations were stronger among ever-smokers compared to never-smokers. These findings support the construct validity of HAA as a novel quantitative phenotype of subclinical lung injury and inflammation that is of biological and physiological importance and that may be a precursor of subclinical ILD.

The associations between HAA and both IL-6 and MMP-7 suggest that HAA identifies areas of interstitial inflammation, extracellular matrix remodeling, and perhaps fibrosis in some cases. IL-6 is a pro-inflammatory cytokine and its serum levels are elevated in acute lung injury [32, 33]. IL-6 has been implicated in chronic obstructive pulmonary disease [34], acute respiratory distress syndrome [35], and certain types of ILD [36]. IL-6 levels have also been linked with reduced FVC percent in population-based cohorts [37, 38]. IL-6 induces hepatic production of CRP and other downstream inflammatory mediators [12]. While IL-6 levels often correlate with CRP, there are a number of conditions where the levels of the two biomarkers do not track each other [39-41], suggesting that there are additional pathways that regulate these biomarkers, which may explain why we did not see an association between HAA and CRP in our study. MMP-7 is thought to play an important role in the normal response to epithelial injury [42]. Epithelial expression of MMP-7 is increased following injury and in the setting of both lung inflammation and fibrosis [18-20, 43, 44]. We found that the association between HAA and serum MMP-7 (and to a lesser extent IL-6) was stronger among ever-smokers, providing support for HAA as a measure of cigarette smoke-induced alveolar remodeling.

While in some individuals HAA might represent hydrostatic pulmonary edema, pulmonary infection, malignant or pre-malignant lesions, or basilar atelectasis due to obesity or incomplete inspiration, the totality of our findings suggests that HAA identifies abnormalities in lung structure with biological and physiological characteristics of subclinical ILD. We found no evidence of strong confounding by cardiac function, BMI, waist circumference, or total volume of imaged lung. MESA participants were generally well at the time of enrollment and were rescheduled or excluded if they had an acute



infectious process or clinically-diagnosed heart failure, respectively. The overall good health of MESA participants decreases the likelihood that HAA reflects the participants' inability to perform a full inspiratory maneuver. A particular strength of our study lies in the consistency of expected changes across a number of radiologic, biologic and physiologic measurements as well as evidence of effect modification by smoking, which would not be expected if HAA represented left ventricular filling pressures or obesity.

Others have used alternative definitions of HAA (-700 to 0 HU, -700 to -500 HU) [45-47], histogram characteristics, and other automated methods [48-51], including texture-based methods [52], to identify and characterize clinically evident ILD, but not subclinical changes. Recent studies have examined the associations between visually-identified ILA and mortality [9], but ours is the first study of HAA as a quantitative measure of lung injury and inflammation that is associated with a higher rate of death in community dwelling adults sampled without regard to lung disease, symptoms, or smoking status. Our results were consistent across the entire spectrum of HAA, and were particularly strong even after exclusion of individuals above the 90<sup>th</sup> percentile of HAA, a group who might have clinically identifiable ILD. The majority of participants had HAA involving less than 10% of imaged lung, suggesting that even small amounts of increased lung attenuation, which might be difficult to detect with the human eye, may identify individuals at risk for ILD. If validated, investigators may be able to use HAA to study causes of early injury, inflammation, and extracellular matrix remodeling of the lung, even before a radiologist identifies the presence of interstitial lung abnormalities. Such studies might allow the identification of novel risk factors and biological pathways for ILD in humans, setting the stage for future clinical trials aimed at primary and secondary prevention of ILD [53].

There are several limitations to our study. First, we lack pathologic correlates of disease against which HAA can be validated. This was a study of subclinical disease in community-dwelling adults unselected for any respiratory symptoms, and therefore with no available pathologic samples. However, we also measured HAA in a second cohort of adults with clinically-diagnosed ILD, most of whom had IPF diagnosed by ATS criteria, and we report HAA values that are significantly higher than those of MESA participants. Second, HAA was assessed on cardiac CTs, which do not image the entire lung, but which have been shown to be useful in examining emphysema [31, 54, 55]. We have previously shown that HAA on cardiac CT agrees strongly with HAA on full-lung CT scans [10]. Third, we report cross-sectional analyses between HAA and biomarkers, which limits inferences about any causal relationships. However, prior studies have firmly established MMP-7 as a biomarker of lung injury and ILD, IL-6 has been well described in the literature as a marker of inflammation, and our ILA and mortality analyses take place over a median follow-up time of 10-12 years. Fourth, we lacked baseline assessment of ILA and therefore can only report the period cross-sectional associations between HAA and ILA. Given the long follow-up period in our study and the 10-year difference between assessment of HAA and ILA, we believe that at least in some cases, HAA precedes the development of ILA. However, the odds ratios we report should not be interpreted as incidence rate ratios.

In summary, greater volumes of increased lung attenuation measured using quantitative CT densitometry are associated with higher serum IL-6 and MMP-7 levels, reductions in FVC,

an increased odds of ILA, and an increased rate of all-cause mortality independent of potential confounding factors among community-dwelling adults. Our data suggest that HAA is a novel quantitative measure of subclinical lung injury, inflammation, and possibly early extracellular matrix remodeling that may be a CT-based risk factor for the development of interstitial lung abnormalities and disease. Future studies should focus on factors that influence HAA in at-risk groups, such as smokers or older adults, and should strive to include HAA in clinical prediction models for incident ILD. Such studies will lead to clinical trials of interventions to prevent ILD.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

**Funding:** This research was supported by grants and contracts R01 HL103676, R01 HL077612, R01 HL114626, RC1-100543 and R01-HL083091, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, and T32 HL105323 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040 and UL1-RR-025005 from NCRR/NCATS. This project was funded in part by the Pulmonary Fibrosis Foundation. The authors thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at <http://www.mesa-nhlbi.org>.

## References

1. Selman M, Pardo A. Alveolar epithelial cell disintegration and subsequent activation: a key process in pulmonary fibrosis. *Am J Respir Crit Care Med*. 2012; 186(2):119–121. [PubMed: 22798412]
2. Zoz DF, Lawson WE, Blackwell TS. Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. *Am J Med Sci*. 2011; 341(6):435–438. [PubMed: 21613930]
3. Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, Travis WD, McCoy JP Jr, May RM, Wu HP, Nguyen DM, Arcos-Burgos M, MacDonald SD, Gochuico BR. Early interstitial lung disease in familial pulmonary fibrosis. *Am J Respir Crit Care Med*. 2007; 176(7):698–705. [PubMed: 17641157]
4. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. *Am J Respir Crit Care Med*. 2012; 185(11):1147–1153. [PubMed: 22366047]
5. Kropski JA, Pritchett JM, Zoz DF, Crossno PF, Markin C, Garnett ET, Degryse AL, Mitchell DB, Polosukhin VV, Rickman OB, Choi L, Cheng DS, McConaha ME, Jones BR, Gleaves LA, McMahon FB, Worrell JA, Solus JF, Ware LB, Lee JW, Massion PP, Zaynagetdinov R, White ES, Kurtis JD, Johnson JE, Groshong SD, Lancaster LH, Young LR, Steele MP, Phillips JA Iii, Cogan JD, Loyd JE, Lawson WE, Blackwell TS. Extensive Phenotyping of Individuals At-risk for Familial Interstitial Pneumonia Reveals Clues to the Pathogenesis of Interstitial Lung Disease. *Am J Respir Crit Care Med*. 2014
6. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, Estepar RS, Lynch DA, Brehm JM, Andriole KP, Diaz AA, Khorasani R, D'Aco K, Sciruba FC, Silverman EK, Hatabu H, Rosas IO, Investigators CO. Lung volumes and emphysema in smokers with interstitial lung abnormalities. *N Engl J Med*. 2011; 364(10):897–906. [PubMed: 21388308]
7. Doyle TJ, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Divo MJ, Celli BR, Sciruba FC, Silverman EK, Hatabu H, Rosas IO, Hunninghake GM, Investigators CO. Interstitial lung abnormalities and reduced exercise capacity. *Am J Respir Crit Care Med*. 2012; 185(7):756–762. [PubMed: 22268134]
8. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, Nishino M, Araki T, Zazueta OE, Kurugol S, Ross JC, San Jose Estepar R, Murphy E, Steele MP, Loyd JE, Schwarz MI, Fingerlin TE, Rosas IO, Washko GR, O'Connor GT, Schwartz DA. MUC5B promoter

polymorphism and interstitial lung abnormalities. *N Engl J Med.* 2013; 368(23):2192–2200. [PubMed: 23692170]


9. Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, Okajima Y, Dupuis J, Latourelle JC, Cho MH, El-Chemaly S, Coxson HO, Celli BR, Fernandez IE, Zazueta OE, Ross JC, Harmouche R, Estepar RS, Diaz AA, Sigurdsson S, Gudmundsson EF, Eiriksdottir G, Aspelund T, Budoff MJ, Kinney GL, Hokanson JE, Williams MC, Murchison JT, MacNee W, Hoffmann U, O'Donnell CJ, Launer LJ, Harris TB, Gudnason V, Silverman EK, O'Connor GT, Washko GR, Rosas IO, Hunninghake GM. Evaluation of CLtIPSEI, Investigators CO. Association Between Interstitial Lung Abnormalities and All-Cause Mortality. *JAMA.* 2016; 315(7):672–681. [PubMed: 26881370]
10. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG. Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. *Am J Respir Crit Care Med.* 2009; 180(5):407–414. [PubMed: 19542480]
11. Kliment CR, Araki T, Doyle TJ, Gao W, Dupuis J, Latourelle JC, Zazueta OE, Fernandez IE, Nishino M, Okajima Y, Ross JC, Estepar RS, Diaz AA, Lederer DJ, Schwartz DA, Silverman EK, Rosas IO, Washko GR, O'Connor GT, Hatabu H, Hunninghake GM. A comparison of visual and quantitative methods to identify interstitial lung abnormalities. *BMC Pulm Med.* 2015; 15:134. [PubMed: 26514822]
12. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. *Proc Natl Acad Sci U S A.* 1987; 84(20):7251–7255. [PubMed: 2444978]
13. Kushner I, Feldmann G. Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. *J Exp Med.* 1978; 148(2):466–477. [PubMed: 702046]
14. Greene KE, Wright JR, Steinberg KP, Ruzinski JT, Caldwell E, Wong WB, Hull W, Whitsett JA, Akino T, Kuroki Y, Nagae H, Hudson LD, Martin TR. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. *Am J Respir Crit Care Med.* 1999; 160(6):1843–1850. [PubMed: 10588595]
15. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K, Kohno N. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. *Am J Respir Crit Care Med.* 2002; 165(3):378–381. [PubMed: 11818324]
16. Greene KE, King TE Jr, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS, Nagae H, Mason RJ. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. *Eur Respir J.* 2002; 19(3):439–446. [PubMed: 11936520]
17. Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI, King TE Jr. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. *Chest.* 2009; 135(6):1557–1563. [PubMed: 19255294]
18. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, Li K, Choi J, Vuga LJ, Lindell KO, Klesen M, Zhang Y, Gibson KF. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2012; 185(1):67–76. [PubMed: 22016448]
19. Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, Sciruba F, Dauber J, Selman M, Gochuico BR, Kaminski N. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Med.* 2008; 5(4):e93. [PubMed: 18447576]
20. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L, Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller RA. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. *Proc Natl Acad Sci U S A.* 2002; 99(9):6292–6297. [PubMed: 11983918]
21. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-ethnic

- study of atherosclerosis: objectives and design. *Am J Epidemiol.* 2002; 156(9):871–881. [PubMed: 12397006]
22. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S, Bild DE, Williams OD, Detrano RC. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. *Radiology.* 2005; 234(1):35–43. [PubMed: 15618373]
  23. Hoffman EA, Jiang R, Baumhauer H, Brooks MA, Carr JJ, Detrano R, Reinhardt J, Rodriguez J, Stukovsky K, Wong ND, Barr RG. Reproducibility and validity of lung density measures from cardiac CT Scans--The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. *Acad Radiol.* 2009; 16(6):689–699. [PubMed: 19427979]
  24. Gevenois PA, de Maertelaer V, De Vuyst P, Zanen J, Yernault JC. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. *Am J Respir Crit Care Med.* 1995; 152(2):653–657. [PubMed: 7633722]
  25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET. Standardisation of spirometry. *Eur Respir J.* 2005; 26(2):319–338. [PubMed: 16055882]
  26. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. *Chest.* 2010; 137(1):138–145. [PubMed: 19741060]
  27. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med.* 2002; 166(1):111–117. [PubMed: 12091180]
  28. Couper D, LaVange LM, Han M, Barr RG, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG, Rennard S, Group SR. Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Thorax.* 2014; 69(5):491–494.
  29. Hoffman EA, Ahmed FS, Baumhauer H, Budoff M, Carr JJ, Kronmal R, Reddy S, Barr RG. Variation in the percent of emphysema-like lung in a healthy, nonsmoking multiethnic sample. The MESA lung study *Ann Am Thorac Soc.* 2014; 11(6):898–907. [PubMed: 24983825]
  30. Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, Diaz A, Sciruba FC, Hunninghake GM, San Jose Estepar R, Silverman EK, Rosas IO, Hatabu H. Identification of early interstitial lung disease in smokers from the COPD Gene Study. *Acad Radiol.* 2010; 17(1):48–53. [PubMed: 19781963]
  31. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright PL, Kawut SM, Kronmal R, Lederer D, Lima JA, Lovasi GS, Shea S, Barr RG. Association between emphysema-like lung on cardiac computed tomography and mortality in persons without airflow obstruction: a cohort study. *Ann Intern Med.* 2014; 161(12):863–873. [PubMed: 25506855]
  32. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. *J Clin Invest.* 2001; 107(12): 1529–1536. [PubMed: 11413160]
  33. Zhang H, Neuhofer P, Song L, Rabe B, Lesina M, Kurkowski MU, Treiber M, Wartmann T, Regner S, Thorlacius H, Saur D, Weirich G, Yoshimura A, Halangk W, Mizgerd JP, Schmid RM, Rose-John S, Algul H. IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. *J Clin Invest.* 2013; 123(3):1019–1031. [PubMed: 23426178]
  34. Garcia-Rio F, Miravittles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, Sobradillo V, Ancochea J, Committee ESS. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. *Respir Res.* 2010; 11:63. [PubMed: 20500811]
  35. Hoeboer SH, Groeneveld AB, van der Heijden M, Oudemans-van Straaten HM. Serial inflammatory biomarkers of the severity, course and outcome of late onset acute respiratory distress syndrome in critically ill patients with or at risk for the syndrome after new-onset fever. *Biomark Med.* 2015; 9(6):605–616. [PubMed: 26079964]


36. Shahar I, Fireman E, Topilsky M, Grief J, Kivity S, Spierer Z, Ben Efraim S. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. *Clin Immunol Immunopathol.* 1996; 79(3):244–251. [PubMed: 8635282]
37. Chang SS, Vaz Fragoso CA, Van Ness PH, Fried LP, Tinetti ME. Association between combined interleukin-6 and C-reactive protein levels and pulmonary function in older women: results from the Women's Health and Aging Studies I and II. *J Am Geriatr Soc.* 2011; 59(1):113–119. [PubMed: 21226682]
38. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, Olafsson I, Benediktsdottir B, Janson C, Buist AS, Gislason T. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. *Respir Med.* 2009; 103(10):1548–1553. [PubMed: 19427181]
39. Lee BT, Ahmed FA, Hamm LL, Teran FJ, Chen CS, Liu Y, Shah K, Rifai N, Batuman V, Simon EE, He J, Chen J. Association of C-reactive protein, tumor necrosis factor- $\alpha$ , and interleukin-6 with chronic kidney disease. *BMC Nephrol.* 2015; 16:77. [PubMed: 26025192]
40. Czarkowska-Paczek B, Bartlomiejczyk I, Gabrys T, Przybylski J, Nowak M, Paczek L. Lack of relationship between interleukin-6 and CRP levels in healthy male athletes. *Immunol Lett.* 2005; 99(1):136–140. [PubMed: 15894122]
41. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. *Arterioscler Thromb Vasc Biol.* 2002; 22(10):1668–1673. [PubMed: 12377747]
42. Gharib SA, Altemeier WA, Van Winkle LS, Plopper CG, Schlesinger SY, Buell CA, Brauer R, Lee V, Parks WC, Chen P. Matrix metalloproteinase-7 coordinates airway epithelial injury response and differentiation of ciliated cells. *Am J Respir Cell Mol Biol.* 2013; 48(3):390–396. [PubMed: 23258229]
43. Villar J, Cabrera-Benitez NE, Ramos-Nuez A, Flores C, Garcia-Hernandez S, Valladares F, Lopez-Aguilar J, Blanch L, Slutsky AS. Early activation of pro-fibrotic WNT5A in sepsis-induced acute lung injury. *Crit Care.* 2014; 18(5):568. [PubMed: 25331176]
44. Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, Parks WC. Matrilysin expression and function in airway epithelium. *J Clin Invest.* 1998; 102(7):1321–1331. [PubMed: 9769324]
45. Shin KE, Chung MJ, Jung MP, Choe BK, Lee KS. Quantitative computed tomographic indexes in diffuse interstitial lung disease: correlation with physiologic tests and computed tomography visual scores. *J Comput Assist Tomogr.* 2011; 35(2):266–271. [PubMed: 21412102]
46. Matsuoka S, Yamashiro T, Matsushita S, Kotoku A, Fujikawa A, Yagihashi K, Nakajima Y. Quantitative CT evaluation in patients with combined pulmonary fibrosis and emphysema: correlation with pulmonary function. *Acad Radiol.* 2015; 22(5):626–631. [PubMed: 25728361]
47. Matsuoka S, Yamashiro T, Matsushita S, Fujikawa A, Kotoku A, Yagihashi K, Kurihara Y, Nakajima Y. Morphological disease progression of combined pulmonary fibrosis and emphysema: comparison with emphysema alone and pulmonary fibrosis alone. *J Comput Assist Tomogr.* 2015; 39(2):153–159. [PubMed: 25474146]
48. Maldonado F, Moua T, Rajagopalan S, Karwoski RA, Raghunath S, Decker PA, Hartman TE, Bartholmai BJ, Robb RA, Ryu JH. Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. *Eur Respir J.* 2014; 43(1):204–212. [PubMed: 23563264]
49. Noor NM, Than JC, Rijal OM, Kassim RM, Yunus A, Zeki AA, Anzidei M, Saba L, Suri JS. Automatic lung segmentation using control feedback system: morphology and texture paradigm. *J Med Syst.* 2015; 39(3):22. [PubMed: 25666926]
50. Moon JW, Bae JP, Lee HY, Kim N, Chung MP, Park HY, Chang Y, Seo JB, Lee KS. Perfusion- and pattern-based quantitative CT indexes using contrast-enhanced dual-energy computed tomography in diffuse interstitial lung disease: relationships with physiologic impairment and prediction of prognosis. *Eur Radiol.* 2015
51. Depeursinge A, Chin AS, Leung AN, Terrone D, Bristow M, Rosen G, Rubin DL. Automated classification of usual interstitial pneumonia using regional volumetric texture analysis in high-resolution computed tomography. *Invest Radiol.* 2015; 50(4):261–267. [PubMed: 25551822]

52. Xu Y, van Beek EJ, Hwanjo Y, Guo J, McLennan G, Hoffman EA. Computer-aided classification of interstitial lung diseases via MDCT: 3D adaptive multiple feature method (3D AMFM). *Acad Radiol.* 2006; 13(8):969–978. [PubMed: 16843849]
53. Lederer DJ. Secondary prevention of idiopathic pulmonary fibrosis: catching the horse still in the barn. *Am J Respir Crit Care Med.* 2012; 185(7):697–699. [PubMed: 22467803]
54. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, Jiang R, Kawut SM, Kronmal RA, Lima JA, Shahar E, Smith LJ, Watson KE. Percent emphysema, airflow obstruction, and impaired left ventricular filling. *N Engl J Med.* 2010; 362(3):217–227. [PubMed: 20089972]
55. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG. Group RTS. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet.* 2015; 386(9991):360–368. [PubMed: 26026936]






**Figure 1.** (A) Boxplots of HAA values for 6,813 MESA participants and 48 adults with clinically diagnosed interstitial lung disease enrolled in the Lung Transplant Body Composition Study. Solid horizontal lines represent the median HAA value. Boxes are bound by the upper and lower quartiles. Whiskers extend to 1.5 times the interquartile range. Outliers are represented by open circles. Wilcoxon rank sum test  $p$  value  $< 0.001$ . (B-E) Selected CT scan images from 4 MESA participants with elevated HAA. (B) Peripheral basilar ground glass abnormality with HAA=8.8% of the imaged lung. (C) Ground-glass opacity with HAA=10.0% of the imaged lung. (D) Early peripheral reticular and cystic changes with HAA=10.2% of the imaged lung. (E) Diffuse ground glass abnormality and an area of peripheral reticular changes with HAA=27.7% of imaged lung. All participants had ILA on follow-up CT scans at MESA exam 5 (median follow-up time 9.5 years). None of the participants were clinically diagnosed with ILD.



**Figure 2.**

Boxplots of exercise capacity at 10.8 years of follow-up in 30 cases with elevated HAA (>7.5%) and 59 controls without elevated HAA on MESA baseline CT scans. O<sub>2</sub> pulse,  $\dot{V}E/\dot{V}CO_2$  and PetCO<sub>2</sub> were measured at peak exercise. Dots represent individual predicted values adjusted for age and gender. Solid horizontal lines represent the median HAA value. Boxes are bound by the upper and lower quartiles. Whiskers extend to 1.5 times the interquartile range.





Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript







**Figure 3.**

Continuous associations between HAA and (a) MMP-7 (overall and stratified by smoking status) at baseline among 908 MESA participants, (b) IL-6 (overall and stratified by smoking status) at baseline among 6,621 MESA participants, (c) ILA 9.5 years following HAA measurement among 2,430 MESA participants, and (d) mortality over 12.2 years of follow-up among 6,808 MESA participants. All models adjusted for age, gender, race/ethnicity, educational attainment, height, BMI, waist circumference, glomerular filtration rate (GFR), study site, mA dose, total volume imaged lung and percent emphysema; overall models also adjusted for smoking status and cigarette pack-years. (a) Overall p for association 0.01, p for non-linearity 0.37; among ever-smokers, p for association <0.001, p for non-linearity 0.70; among never-smokers, p for association 0.69, p for non-linearity 0.18; p for smoking interaction <0.001. (b) Overall p for association <0.001, p for non-linearity 0.005; among ever-smokers p for association <0.001; p for non-linearity 0.17; among never-smokers p for association 0.28; p for non-linearity 0.02; p for smoking interaction 0.11. (c) P for association <0.001; p for non-linearity 0.05. (d) P for association <0.001. Black points are the overall effect estimate; thin dashed lines are the 95% confidence bands; red points are the effect estimate among ever-smokers; blue points are the effect estimate among never-



smokers. Each point in the graphs and each vertical hashmark in the rug plot along the x-axis represent one study participant.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

**Cross-sectional associations between HAA and serum biomarkers of lung injury, extracellular matrix remodeling and inflammation at the MESA baseline exam stratified by smoking status**

	Overall		Ever-smokers		Never-smokers		P for smoking interaction	
	Percent change in biomarker*	P value	Percent change in biomarker*	P value	Percent change in biomarker*	P value	Percent change in biomarker*	P value
MMP-7, ng/mL	6.26 (1.29 to 11.47)	0.01	15.45 (7.91 to 23.53)	<0.001	1.39 (-5.36 to 8.62)	0.69		<0.001
SP-A, ng/mL	2.36 (-6.28 to 11.80)	0.60	8.60 (-3.52 to 22.30)	0.17	0.61 (-11.95 to 14.97)	0.93		0.14
CRP, mg/L	-2.73 (-8.82 to 3.76)	0.40	4.18 (-5.16 to 14.45)	0.39	-6.03 (-14.16 to 2.86)	0.18		0.88
IL-6, pg/mL	8.78 (4.77 to 12.95)	<0.001	17.70 (11.38 to 24.38)	<0.001	2.88 (-2.34 to 8.39)	0.28		0.11

HAA = high attenuation areas; MMP-7 = matrix metalloproteinase-7; SP-A = surfactant protein-A, CRP = c-reactive protein; IL-6 = interleukin-6 For MMP-7 and SP-A, n=908 (341 cases defined as having HAA>9% and a randomly selected subcohort of 600 MESA participants; 33 participants in the subcohort also met case definition); for CRP, n=6761; for IL-6, n=6621.

\* Adjusted for age, gender, race/ethnicity, educational attainment, height, BMI, waist circumference, smoking status, cigarette pack-years, glomerular filtration rate (GFR), study site, mA dose, total volume of imaged lung and percent emphysema. Adjustment for smoking status and pack-years was excluded from smoking-stratified models. All covariates measured at baseline examination in 2000 to 2002. Percent change is reported per 2-fold increase in HAA.

**Table 2**  
**Associations between baseline HAA and ILA at 9.5 years of follow-up in MESA participants.\***

	HAA				P for trend	Overall	P value
	Quartile 1	Quartile 2	Quartile 3	Quartile 4			
Number with ILA	61	72	72	101		306	
ILA prevalence, %	8.4	9.9	9.9	13.9	<0.001	10.5	
<b>OR (95% CI)</b>						<b>OR (95% CI) per doubling of HAA</b>	
Unadjusted	Ref	1.14 (0.80 to 0.84)	1.20 (0.84 to 1.72)	1.76 (1.25 to 2.46)	<0.001	1.47 (1.21 to 1.79)	<0.001
Adjusted <sup>†</sup>	Ref	1.42 (0.93 to 2.17)	1.79 (1.11 to 2.89)	3.07 (1.77 to 5.33)	<0.001	1.95 (1.43 to 2.65)	<0.001
Adjusted, stratified by smoking status; <sup>‡</sup>							
Ever-smokers	Ref	1.14 (0.66 to 1.99)	1.53 (0.84 to 2.81)	2.31 (1.13 to 4.73)	0.009	2.38 (1.57 to 3.60)	<0.001
Never-smokers	Ref	2.34 (1.18 to 4.64)	2.55 (1.15 to 5.65)	5.55 (2.24 to 13.77)	<0.001	1.59 (0.99 to 2.55)	0.053

HAA = high attenuation areas; ILA = interstitial lung abnormalities; OR = odds ratio; CI = confidence interval

\* ILA assessment was completed on 2,907 MESA participants who also had complete HAA data, over 9.5 years of follow-up. 477 of these participants had scans read as equivocal for ILA and were excluded from analyses.

<sup>†</sup> Adjusted for age, gender, race/ethnicity, educational attainment, height, BMI, waist circumference, smoking status, cigarette pack-years, glomerular filtration rate (GFR), study site, mA dose, total volume of imaged lung and percent emphysema. Adjustment for smoking status and pack-years was excluded from smoking-stratified models. All covariates measured at baseline examination in 2000 to 2002.

<sup>‡</sup> P for interaction 0.24.

**Table 3**  
**Associations between baseline HAA and mortality over 12.2 years of follow-up in 6,808 MESA participants**

	HAA				Overall	P for trend	P value
	Quartile 1	Quartile 2	Quartile 3	Quartile 4			
Number at-risk	1699	1699	1700	1699	6808		
Number of decedents	252	237	283	321	1093		
Person-years of observation	19,010	18,805	18,844	18,347	75,006		
Mortality rate per 1,000 PY	13.3	12.6	15.0	17.5	14.6		
<b>HR (95% CI)</b>							<b>HR (95% CI) per doubling of HAA</b>
Model 1 <sup>*</sup>	Ref	1.15 (0.94 to 1.40)	1.51 (1.23 to 1.87)	1.94 (1.53 to 2.46)	1.58 (1.39 to 1.79)	<0.001	<0.001
Model 2 <sup>‡</sup>	Ref	1.15 (0.95 to 1.41)	1.52 (1.23 to 1.88)	1.91 (1.51 to 2.43)	1.55 (1.37 to 1.77)	<0.001	<0.001
Model 2, stratified by smoking status <sup>‡</sup>							
Ever-smokers	Ref	1.35 (1.05 to 1.72)	1.65 (1.27 to 2.15)	2.42 (1.81 to 3.22)	1.78 (1.50 to 2.11)	<0.001	<0.001
Never-smokers	Ref	1.02 (0.73 to 1.43)	1.40 (0.99 to 2.00)	1.55 (1.02 to 2.35)	1.38 (1.12 to 1.70)	0.02	0.002

PY = person-years, HAA = high attenuation areas; HR = hazard ratio; CI = confidence interval

<sup>\*</sup> Adjusted for age, gender, race/ethnicity, educational attainment, height, BMI, waist circumference, smoking status, cigarette pack-years, glomerular filtration rate (GFR), study site, mA dose, total volume of imaged lung and percent emphysema. Adjustment for smoking status and pack-years was excluded from smoking-stratified models. All covariates measured at baseline examination in 2000 to 2002.

<sup>‡</sup> Model 2 is additionally adjusted for alcohol use, exercise, coronary artery calcium, diabetes medication use, insulin use, fasting glucose level, hypertension, antihypertensive medication use, systolic and diastolic blood pressures, cholesterol medication use, total and high-density lipoprotein cholesterol levels, c-reactive protein level, d-dimer level and history of cancer.

<sup>‡</sup>P for interaction 0.56.